PUBLICATIONS
DR. STEPHANIE DU FOUR

PUBLICATIONS


DR. STEPHANIE DU FOUR

Internationale artikels peer reviewed

Lv S, Teugels E, Sadones J, Quartier E, Huylebrouck M, Du Four S, et al. Correlation between IDH1 gene mutation status and survival of patients treated for recurrent glioma. Anticancer Res. 2011; 31(12):4457-4463.

Wilgenhof S, Morlion V, Seghers AC, Du Four S et al. Sarcoidosis in a Patient with Metastatic Melanoma Sequentially Treated with Anti-CTLA-4 Monoclonal Antibody and Selective BRAF Inhibitor. Anticancer Res. 2012; 32(4):1355-1359.

Lv S, Teugels E, Sadones J, De Brakeleer S, Duerinck J, Du Four S, et al. Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab. Int J Oncol. 2012 Sep; 41(3):1029-35.

Du Four S, Wilgenhof S, Duerinck J, Michotte A, Van Binst A, De Ridder M, Neyns B. Radiation necrosis of the brain in melanoma patients successfully treated with ipilimumab, three case studies. Eur J Cancer. 2012 Nov; 48(16):3045-51.

Wilgenhof S, Du Four S, Everaert H, Neyns B. Atypical patterns of response in patients with pretreated metastatic melanoma who received ipilimumab 3 mg/kg in a European expanded access programme: five illustrative case reports. Cancer Invest. 2012 Dec; 30(10):712-20.

Wilgenhof S, Du Four S, Vandenbroucke F, Everaert H, Salmon I, Liénard D, Marmol VD, Neyns B. Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma. J Immunother. 2013 Apr;36(3):215-22.

Du Four S, Hong A, Chan M, Charakidis M, Duerinck J, Wilgenhof S, Wang W, Feng L, Michotte A, Okera M, Shivalingam B, Fogarty G, Kefford R, Neyns B. Symptomatic Histologically Proven Necrosis of Brain following Stereotactic Radiation and Ipilimumab in Six Lesions in Four Melanoma Patients. Case Rep Oncol Med. 2014;2014:417913.

Maenhout SK, Du Four S, Corthals J, Neyns B, Thielemans K, Aerts JL. AZD1480 delays tumor growth in a melanoma model while enhancing the suppressive activity of myeloid-derived suppressor cells. Oncotarget. 2014 Aug 30;5(16):6801-15.

Du Four S, Maenhout SK, De Pierre K, Renmans D, Niclou SP, Thielmans K, Neyns B and Aerts J. Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model. OncoImmunology 2015. Jan 22; 4(4):e998107.

Duerinck J, Du Four S, Sander W, Van Binst AM, Everaert H, Michotte A, Hau P, Neyns B. Sunitinib Malate plus Lomustine for Patients with Temozolomide-refractory Recurrent Anaplastic or Low-grade Glioma. Anticancer Res. 2015 Oct;35(10):5551-7.

Duerinck J, Du Four S, Vandervorst F, D'Haene N, Le Mercier M, Michotte A, Van Binst AM, Everaert H, Salmon I, Bouttens F, Verschaeve V, Neyns B. Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma. J Neurooncol. 2016 May;128(1):147-55.

Van Lint S, Renmans D, Broos K, Goethals L, Maenhout S, Benteyn D, Goyvaerts C, Du Four S, et al. Intratumoral Delivery of TriMix mRNA Results in T-cell Activation by Cross-Presenting Dendritic Cells. Cancer Immunol Res. 2016 Feb;4(2):146-56.

Du Four S, Maenhout SK, Benteyn D, De Keersmaecker B, Duerinck J, Thielemans K, Neyns B and Aerts JL. Disease progression in recurrent glioblastoma patients treated with the VEGFR- inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion. Cancer Immunology Immunotherapy. Cancer Immunol Immunother. 2016 Jun;65(6):727-40.

Du Four S, Maenhout SK, Niclou S, Thielemans K, Neyns B and Joeri AL. Combined VEGFR and CTLA-4 blockade increases the antigen-presenting function of intratumoral DCs and reduces the suppressive capacity of intratumoral MDSCs in subcutaneous and intracranial melanoma mouse models. American Journal of Cancer Research. Am J Cancer Res. 2016 Nov 1;6(11):2514-2531. eCollection 2016

Demeulenaere M, Duerinck J, Du Four S, Fostier K, Michotte A, Neyns B. Bone Marrow Metastases from a 1p/19q Co-deleted Oligodendroglioma - A Case Report. Anticancer Res. 2016 Aug;36(8):4145-9.

Duerinck J, Du Four S, Bouttens F, Andre C, Verschaeve V, Van Fraeyenhove F, Chaskis C, D'Haene N, Le Mercier M, Rogiers A, Michotte A, Salmon I, Neyns B. Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma. 2018 Jan;136(1):115-125.

Du Four S, Mertens R, Wiels W, De Keyser J, Bissay V, Flamez A. Meningoencephaloradiculitis following infection with tick borne encephalitis virus: case report and review of the literature. Acta Neurol Belg. 2018 Mar;118(1):93-96.

Wiels WA, Du Four S, Seynaeve L, Flamez A, Tousseyn T, Thal D, D'Haeseleer M. Early-Onset Creutzfeldt-Jakob Disease Mimicking Immune-Mediated Encephalitis. Front Neurol. 2018 Apr 10;9:242

Du Four S, Janssen Y, Michotte A, Van Binst AM, Van den Begin R, Duerinck J, Neyns B. Focal radiation necrosis of the brain in patients with melanoma brain metastases treated with pembrolizumab. Cancer Med. 2018 Aug 21.

Awada G, Ben Salama L, De Cremer J, Schwarze JK, Fischbuch L,  Seynaeve L,  Du Four S, Vanbinst AM, Michotte A, Everaert H,  Rogiers A, Theuns P, Duerinck J, Neyns B.

Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx). J Immunother Cancer. 2020 Oct;8(2):e001146. doi: 10.1136/jitc-2020-001146.

 

 

Overige

Du Four S, Wilgenhof S, Vander Stichele D, D’Haens J, Neyns B. Brain metastasis in melanoma patients treated with autologous dendritic cell therapy and/or ipilimumab, a single institution experience. EORTC-EANO conference meeting. 2011.Poster presentation.

Vander Stichele D, Wilgenhof S, Vandenbroucke F, Du Four S et al. Single-institution experience in an extended access program with the CTLA-4 blocking monoclonal antibody ipilimumab in pretreated melanoma patients. EADO. 2011.Poster presentation.

Verschaeve V, D’Hondt L, Verbeke L, Du Four S et al. CeCil: A randomized, non-comparative phase II clinical trial of the effect of radiation therapy (RT) plus temozolomide (TMZ) combined with cilengitide or cetuximab on the 1-year overall survival of patients with newly diagnosed MGMT-promoter unmethylated . ASCO meeting abstracts. 2011.Poster presentation.

Du Four S, Wilgenhof S, Seghers A, Duerinck J, Neyns B. Ipilimumab in patients with melanoma brain metastases, a single-center experience in an expanded access program. ASCO meeting abstracts. 2012.Publication.

Wilgenhof S, Seghers A, Du Four S, et al. Single-center experience with ipilimumab in patients with pretreated advanced melanoma. ASCO meeting abstracts. 2012.

Duerinck J, Du Four S, Van Binst A, et al. Phase II trial of sunitinib malate in patients with temozolomide refractory recurrent low-grade and anaplastic gliomas. ASCO meeting abstract.2012. Poster presentation.

Du Four S, Wilgenhof S, Neyns B. ‘Ipilimumab in patients with melanoma brain metastases, a single-center experience in an expanded access program’. EANO 10th meeting 2012. Poster presentation.

Duerinck J, Du Four S, Van Binst A, Everaert H, Michotte A, D’Haens J, Neyns B. Phase II trial of sunitinib malate and lomustine in patients with temozolomide refractory recurrent low-grade and anaplastic glioma. EANO 10th meeting 2012. Poster presentation.

Duerinck J, Du Four S, Van Binst A, Michotte A, D’haens J, Neyns B. Axitinib for the treatment of recurrent glioblastoma - early results from a randomized phase II trial. The European Cancer Congres 2013 (ECCO-ESMO-ESTRO). Poster presentation.

Du Four S, Duerinck J, Wilgenhof S, Van Binst A, D'Haens J, and Neyns B. Changing role of surgical resection in patients with melanoma brain metastases treated with immunotherapy. EANS Annual Meeting 2013. Poster presentation

Duerinck J, Du Four S, Van Binst A, Michotte A, D’haens J, Neyns B. Axitinib for the treatment of recurrent glioblastoma - early results from a randomized phase II trial. EANS Annual Meeting 2013. Poster presentation.

Duerinck J, Du Four S, D’Haens J, Everaert H, Van Binst A, De Raedt S and Neyns B. Value of FET-PET evaluation in patients with recurrent glioblastoma treated with the VEGFR-inhibitor axitinib. 11th meeting of the European association of neuro-oncology (EANO), October 9-12, 2014, Turin, Italy.

Du Four S, Duerinck J, Wilgenhof S, Van Velthoven V, D’Haens J and Neyns B. Local treatment of melanoma brain metastases in patients treated with immunotherapy. Annual Scientific Meeting of the Belgian Society of Neurosurgery. 2015, Brussels, Belgium

Du Four S, Everaert H, Jaudet, C., Michotte A, Duerinck J, Van Velthoven V, Neyns B, and Gläsker S Correlation between dynamic 18F-FET PET and tumor histology in glioma: results of a preliminary analysis. . Annual Scientific Meeting of the Belgian Society of Neurosurgery. 2017, Brussels, Belgium.

Du Four S, Janssen Y, Van Den Begin R, Duerinck J, Glasker S, Van Velthoven V and Neyns B. Neurosurgical treatment for focal post radiation necrosis of the brain following radiosurgery for melanoma brain metastases in patients successfully treated with PD-1 immune checkpoint inhibition. Annual Scientific Meeting of the Belgian Society of Neurosurgery. 2017, Brussels, Belgium.

Du Four S, Nuytemans L, Everaert H, Jaudet C, Michotte A, Duerinck J, Van Velthoven V, Neyns B, Gläsker S. Correlation between dynamic 18F-FET PET and tumor histology in glioma: results of a preliminary analysis. Annual Scientific Meeting of the Belgian Society of Neurosurgery. 2017, Brussels, Belgium

Du Four S, Van Der Veken J, Wanet T, Moens M, Duerinck J, Glasker S and Van Velthoven V. Short term outcome of minimal invasive treatment of hemorrhagic stroke. EANS Annual Meeting Facts and Fiction 2018, Brussels. Belgium

Du Four, J Van Der Veken, J Duerinck, S. Glasker and V. Van Velthoven. Pituitary carcinoma, a case series. Annual Scientific Meeting of the Belgian Society of Neurosurgery. 2020, Brussels, Belgium

LOCATIES

AZ Delta Rumbeke, Deltalaan 1 |
+ 32 51 23 74 46

AZ Delta Roeselare, Brugsesteenweg 90 |
+ 32 51 23 69 80

AZ Delta Menen, Oude Leielaan 6 |
+ 32 51 23 74 46

AZ Delta Torhout, Sint-Rembertlaan 21 |
+ 32 51 23 74 46

Jan Yperman, Briekestraat 12 |
+ 32 57 35 73 45


ONZE ARTSEN
Dr. Olivier Van Damme (diensthoofd)
Dr. Dimitri Vanhauwaert
Dr. Jeroen Van Lerbeirghe
© impressionant | 2019